Key Drivers
- Severe Losses
- Weak Liquidity
- High Intangibles
AIAI Summary
CLVT is a leveraged turnaround—not a cheap compounder—where upside hinges on completing the $600M Life Sciences sale and directing proceeds to meaningful debt reduction while stabilizing declining revenue; avoid treating its low valuation as attractive until free cash flow and core-segment retention prove resilient.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Severe Losses
- •Weak Liquidity
- •High Intangibles
CLVT offers strong gross margins and cash generation, but severe recent losses, weak liquidity, heavy intangibles, and high debt make the seemingly low valuation a high-risk proposition.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Support stabilization
- •Weak momentum
CLVT remains bearish over the last month, with $1.87–$1.89 support critical and a rebound requiring a move above $1.95–$2.00.
Decline accelerated after the $2.16 peak
Sentiment & News
Key News Insights:
- •Cash tender offer
- •Citation Laureates
- •Separate developments
Clarivate paired debt-management actions with high-profile scientific recognition, signaling financial discipline alongside brand-strengthening research leadership.
The debt tender may support balance-sheet flexibility, while the laureate recognition modestly reinforces Clarivate's scientific-data brand
Similar Companies in Technology
Other companies in the same sector with AI ratings